标题
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer
作者
关键词
-
出版物
CLINICAL INFECTIOUS DISEASES
Volume -, Issue -, Pages -
出版商
Oxford University Press (OUP)
发表日期
2018-03-01
DOI
10.1093/cid/ciy175
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib
- (2018) David Ghez et al. BLOOD
- Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis
- (2017) Marine Baron et al. LEUKEMIA & LYMPHOMA
- AtypicalPneumocystis jiroveciipneumonia in previously untreated patients with CLL on single-agent ibrutinib
- (2016) Inhye E. Ahn et al. BLOOD
- Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia
- (2016) Andrea Visentin et al. HEMATOLOGICAL ONCOLOGY
- Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
- (2015) J. C. Byrd et al. BLOOD
- Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies
- (2015) Y Wang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
- (2015) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dual Functions of Bruton's Tyrosine Kinase and Tec Kinase during Fc Receptor-Induced Signaling and Phagocytosis
- (2014) J. Jongstra-Bilen et al. JOURNAL OF IMMUNOLOGY
- Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study
- (2014) Anas Younes et al. LANCET ONCOLOGY
- Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study
- (2014) Jan A Burger et al. LANCET ONCOLOGY
- Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
- (2013) Susan O'Brien et al. LANCET ONCOLOGY
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bruton's Tyrosine Kinase (BTK) and Vav1 Contribute to Dectin1-Dependent Phagocytosis of Candida albicans in Macrophages
- (2013) Karin Strijbis et al. PLoS Pathogens
- Invasive Fungal Infections in Patients with Hematologic Malignancies (Aurora Project): Lights and Shadows During 18-Months Surveillance
- (2012) Maria Teresa Montagna et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
- (2012) Ranjana H. Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain
- (2009) Abdalla J. Mohamed et al. IMMUNOLOGICAL REVIEWS
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
- (2008) Ben De Pauw et al. CLINICAL INFECTIOUS DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started